A single dose of the experimental Ebola vaccine, rVSV-ZEBOV, was highly effective in preventing Ebola virus disease (EVD) among those in contact with patients with confirmed disease, according to the final results from a large trial conducted in Guinea.
The international team of researchers began this open-label, cluster-randomized ring vaccination efficacy trial, called Ebola ça Suffit, in 2015. Involving almost 12 000 people in the coastal region of Basse-Guinea, the study used a “ring vaccination” approach inspired by the strategy used to eradicate smallpox. The investigators vaccinated a ring, or cluster, of all contacts and contacts of contacts of people who had confirmed EVD. Each cluster was made up of about 80 people. In the beginning of the trial, the clusters were randomized to receive the vaccine either immediately after being identified as a contact or after a 21-day delay.
Friedrich M. Ebola Vaccine Found Highly Protective. JAMA. 2017;317(7):687. doi:10.1001/jama.2017.0633
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: